Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016


#522543

100pages

DelveInsight

$ 2000

In Stock

SUMMARY
DelveInsights Report, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Report is to understand the market and pipeline status of the drugs around the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsights Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsights report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer
List of Tables
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, Europe by Country, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, India by State, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, China by Province, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers by Geography 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales-2018 (in million USD)
API Manufacturers for Drug, 2016
Phase III Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, 2016
Discontinued Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, 2016
List of Figures
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, Europe by Country, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, India by State, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, China by Province, 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers by Geography 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales 2018 (in million USD)
Drug, Patent/Exclusivity Expiry (Year), 2016